Conatus Pharmaceuticals Inc (CNAT) Given Average Recommendation of “Buy” by Brokerages

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has received an average recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $12.50.

A number of research analysts have recently commented on the stock. ValuEngine raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 4th. Finally, Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 2nd.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of Conatus Pharmaceuticals during the second quarter valued at about $142,000. Paloma Partners Management Co acquired a new position in shares of Conatus Pharmaceuticals during the second quarter valued at about $547,000. Bank of America Corp DE raised its position in shares of Conatus Pharmaceuticals by 75.7% during the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after buying an additional 60,604 shares during the last quarter. Alambic Investment Management L.P. raised its position in Conatus Pharmaceuticals by 207.0% in the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 178,461 shares in the last quarter. Finally, MYDA Advisors LLC acquired a new position in Conatus Pharmaceuticals in the second quarter worth about $154,000. 33.50% of the stock is owned by institutional investors and hedge funds.

CNAT stock traded down $0.22 during mid-day trading on Friday, reaching $4.36. 404,834 shares of the stock traded hands, compared to its average volume of 520,865. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.35 and a quick ratio of 2.35. Conatus Pharmaceuticals has a 52 week low of $3.22 and a 52 week high of $7.95. The stock has a market capitalization of $139.27 million, a price-to-earnings ratio of -7.15 and a beta of 1.41.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. The company had revenue of $8.77 million during the quarter, compared to analysts’ expectations of $9.06 million. equities analysts expect that Conatus Pharmaceuticals will post -0.61 EPS for the current fiscal year.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Read More: NASDAQ

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply